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receiver operating characteristic curve (ROC) analysis to 
define the cut-off points for significant parameters.  
Results: Median follow-up time was 20.5 months (range 4 – 
91) and 18 months (14-80) for primary and secondary lung 
cancer. RP G1-2 has been observed in 23/54 patients 
(42.59%); no pulmonary toxicity >G2 has occurred, as there 
has been no toxicity of controlateral lung and other organs at 
risk. Univariate statistical analysis showed that 
GTV(p=0.036), PTV (p=0.022), MLD (p=0.003) and V5 
(p=0.002), V10 (p=0.002), V20 (p=0.012), V30 (p=0.002) were 
significant variables for the risk of developing RP. 
Multivariate statistical analysis has found that the predictor 
variables of RP are V5 (p=0.004), V10 (p=0.009), V20 
(p=0.014), V30 (p=0.007) and the MLD (p=0.011). The 
greatest risk was connected to the variable V30 (HR 1.985 ).  
On the ROC curve, the cut-off values of ipsilateral lung 
V5,V10,V20,V30 and MLD were 29.50%,19.50%,9.55%,4.58% 
and 4.7%, respectively (Fig.1). A cutoff of 4.58% for V30 had 
a sensitivity of 80% and specificity of 82.1%. 
 
Conclusions: In our study stereotactic body radiotherapy was 
well tolerated for primary and secondary lung cancer 
treatment. V5, V10, V20, V30 and MLD were significantly 
predictive of RP.  
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Purpose/Objective: Analyse clinical and dosimetric results of 
helical tomotherapy (HT) and rapidarc (RA) in complex 
adjuvant breast and nodes (IMC and supraclavicular nodes) 
irradiation with simultaneous-integrated boost. 
Materials and Methods: Seventy-nine patients were included 
in the study (37 HT and 42 RA). Treatments were in 29 
fractions. Dose prescriptions were 63.8 Gy (HT) and 63.2 Gy 
(RA) in the tumour bed, 52.2 Gy in the breast (HT and RA), 
50.4 Gy in supraclavicular nodes and IMC with HT and 52.2 Gy 
and 49.3 Gy in IMC and supraclavicular nodes with RA. 
Margins to the PTV were larger in the rapidarc group (7mm vs 
5mm). 
Results: For HT cohort, the coverage of clinical target 
volumes (CTV) was as follows: CTV tumour bed: 99,4%±2,4; 
CTV breast: 98,4%±4,3; CTV supraclavicular nodes: 
99,5%±1.2; CTV IMC: 96,5%±13,9. For RA cohort, the coverage 
of CTV was as follows: CTV tumour bed: 99,7%%±0,5, CTV 
breast: 99,3 %±0,7; CTV supraclavicular nodes: 99,6%±1,4; 
CTV IMC: 99,3%±3. For ipsilateral lung, Dmean and V20 were 
13, 5 Gy±1, 4, 20,9%±4,9 (HT) and 13,6 Gy±1,4, 20,1%±3,2 
(RA). Dmean and V30 of the heart were 7,4 Gy±1,4, 1%±1 
(HT) and 10,3 Gy±4,2, 2,5%±3,9 (RA). For controlateral breast 
Dmean was 3, 6 Gy±0,7 (HT) and 4,6 Gy±0,9 (RA). There was 
5% of acute skin toxicity grade ≥ 3 in the two cohorts and 35% 
of oesophageal toxicity grade≤ 2 in HT and 40% in RA. 
Conclusions: Rotational IMRT in complex adjuvant breast and 
nodes irradiation allows a good coverage of target volumes 
with an acceptable acute tolerance. A longer follow-up is 
needed to assess the impact of low doses to healthy 
tissues
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Purpose/Objective: To investigate the feasibility and 
tolerance in the use of adjuvant Intensity Modulated 
Radiation Therapy (IMRT) and simultaneous integrated boost 
(SIB) in patients with a diagnosis of breast cancer after 
breast-conserving surgery (BCS). 
Materials and Methods: Between September 2011 to 
February 2013, 150 women with a diagnosis of breast cancer 
were treated with SIB-IMRT after BCS in our Institution. A 
dose prescription of 50 Gy in 25 fractions was prescribed to 
the whole breast (PTVbreast) and an additional dose of 
radiation on the tumour bed was prescribed (PTVboost). A 
dose prescription of 60 Gy in 25 fractions to PTVboost was 
used in patients with negative margins after surgery, whereas 
if the margins were close (< 1 mm) or positive (without a new 
surgical resection) a dose of 64 Gy was prescribed. All 
patients were followed with periodic clinical evaluation. 
